Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Clinical trial NCT03885089 · COMPLETED

Trial details

NCT number: NCT03885089
Sponsor: Pfizer
Status: COMPLETED
Study type: OBSERVATIONAL

Psoriasis Vulgaris Psoriasis Arthropathica Pustular Psoriasis Erythrodermic Psoriasis

Start date: 2019-10-21
Primary completion: 2024-03-08
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.